BPC-157 vs TB-500: How the Two Differ

What is the difference between BPC-157 and TB-500?

BPC-157 and TB-500 are different molecules from different places. BPC-157 is a synthetic 15-amino-acid peptide whose sequence was taken from a protein found in human gastric juice; it weighs 1,419.5 g/mol and has no natural counterpart that circulates on its own. TB-500 is a trade name for a 7-amino-acid fragment, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, cut from residues 17 to 23 of thymosin beta-4, a 43-residue protein present in nearly every human cell. The fragment weighs 889 g/mol. The full protein weighs 4,963 g/mol and is a different PubChem record, timbetasin, from the fragment.

The two get paired because both are marketed for tendon, ligament and muscle recovery and because a 1:1 blend vial is cheap to make. Their evidence does not travel together. BPC-157 has a large rodent literature and a handful of small human reports, covered in the BPC-157 research guide. The TB-500 fragment has two mouse wound experiments and some culture-dish work; every human study of thymosin beta-4 used the whole protein.

What is actually in a vial labeled TB-500?

The name entered the literature in 2012, when anti-doping chemists identified the N-acetylated 17-23 fragment in a veterinary product aimed at racehorses and greyhounds. That is the molecule the PubChem record and this site's TB-500 card describe. Research-chemical vendors, however, sell both the fragment and the full 43-residue protein under the same name, and the FDA's 2026 briefing document recorded that the names TB-500 and thymosin beta-4 are used interchangeably for substances that are not the same. One vendor-affiliated guide in the dossier calls the fragment a 17-amino-acid peptide, which it is not.

How do the two peptides work?

For the TB-500 fragment the mechanism is unusually well defined. The parent protein sequesters actin monomers, and the seven residues in TB-500 are its actin-binding motif. In a 2003 FASEB Journal study, the intact protein and the seven-residue motif produced near identical endothelial cell migration and vessel sprouting at about 50 nM in culture, while peptides missing any part of the motif were inactive. That experiment is why the fragment exists as a product. It says which part of the molecule is active in a dish, not what any amount does in a person.

BPC-157 has no single defined target. The rodent literature attributes its effects to blood vessel formation and to interactions with growth factor signaling in injured tissue, and a 2026 review places it alongside growth factors as a candidate for tendon and muscle junction repair. A receptor has not been identified. The two peptides are described by the authors of the one combination study as converging on shared downstream pathways, which is also the simplest explanation for why giving both did not add anything.

What has each been studied in?

BPC-157: rats, mostly. Daily systemic injections of 10 mcg/kg or 10 ng/kg through 14 to 21 day models of tendon, muscle, gut and vascular injury, plus animal toxicology up to 20 mg/kg with no toxic dose reached and no study beyond 6 weeks, according to a 2025 systematic review. In people: a 16-patient knee injection chart review, a 12-patient interstitial cystitis pilot, a 2-person infusion pilot and one negative placebo-controlled enema abstract.

The TB-500 fragment: two topical applications of 5 mcg to full thickness skin wounds in diabetic and aged mice, where in the aged mice it promoted repair about as well as the parent protein in a 2003 Wound Repair and Regeneration study. The FDA's 2026 literature search found no article in which the fragment had been given to a human by any route. The full protein has been through a phase 1 intravenous study in 40 volunteers at 42 to 1,260 mg daily for 14 days with no dose-limiting toxicity, a 72-patient pressure ulcer gel trial in which no strength beat placebo, a 700-patient dry eye trial that missed its primary endpoints, and an 18-patient keratopathy trial with a healing trend short of significance. None of that is evidence for a subcutaneous fragment, and none of it produced an approval.

Why are the community schedules so different?

Guides describe BPC-157 once or twice a day and TB-500 twice a week, then weekly. The usual explanation is half-life, and for BPC-157 the animal data do point one way: the FDA's briefing document cites 5.3 minutes in dogs and 15.2 minutes in rats after intravenous dosing. For the TB-500 fragment there is no human or animal pharmacokinetic study at all, so the twice-weekly schedule cannot be a half-life calculation. It is a convention borrowed from rodent wound models in which the protein was applied at wounding and again at 48 hours. The 2 to 2.5 mg loading dose, the 4 to 6 week loading phase and the 12-week cap in some guides are described by their own authors as untested in any human trial of the fragment.

What does the BPC-157 / TB-500 blend vial contain?

The blend is one vial of both peptides at a 1:1 ratio by mass, sold as 5 mg plus 5 mg or 10 mg plus 10 mg. The ratio is fixed at the factory, so a draw that delivers 500 mcg of BPC-157 also delivers 500 mcg of TB-500 and neither can be adjusted on its own. Made up with 2 mL, the 5/5 vial holds 2.5 mg/mL of each peptide and 5 mg/mL in total, so a 10 unit draw on a U-100 syringe carries 250 mcg of each. The same volume in the 10/10 vial carries twice that. The calculator handles the total-concentration arithmetic; what it cannot do is tell which thymosin beta-4 species is in the vial. A blend certificate has to report two peptides, and a single purity figure for a mixture does not say which component an impurity belongs to.

Has the combination been tested?

Not in people. No human study has given BPC-157 and TB-500 together as a course; the closest thing is a four-patient subset of the 2021 knee chart review who received BPC-157 with a compounded thymosin beta-4, with no control group and no stated amount of the thymosin. One animal study exists. A 2026 rat Achilles tendon trial gave 32 rats vehicle, BPC-157 at 10 mcg/kg, TB-500 at 60 mcg/kg, or both, by daily intraperitoneal injection for 30 days after tendon repair. TB-500 alone produced the only statistically significant gain in load to failure. The combination improved one histology score but did not differ from either single agent on any measure. The TB-500 used was described as synthetic thymosin beta-4 from a research supplier and each compound was tested at a single dose, so the result is exploratory. It is also the only direct evidence about the stack, and it does not support the claim that the two are synergistic.

Where do the two stand with regulators?

Both are prohibited in sport at all times: BPC-157 under section S0 of the WADA list as a non-approved substance, and thymosin beta-4 with its derivatives, TB-500 included, under section S2.3, with validated detection methods. Neither is approved as a drug anywhere. Both went before the FDA's Pharmacy Compounding Advisory Committee on July 23, 2026, where agency reviewers recommended against adding either to the 503A bulks list, citing the absence of human data for the fragment and the naming confusion as a patient safety risk. The committee voted 8 to 6, with one abstention, in favor of each. The votes are advisory, no rule has followed, and until one does, neither peptide can be lawfully compounded by a 503A pharmacy.

What this comparison does not establish

Nothing above shows that either peptide heals a human injury, that the fragment sold as TB-500 does anything when injected, or that stacking the two improves on either alone; the one experiment that asked found it did not. The only firm differences are chemical: 15 residues against 7, a known actin-binding motif against an undefined target, and a WADA S0 listing against S2.3. The full protocol tables, with each clinical, preclinical and community row linked to its source, are on the BPC-157, TB-500 and blend compound pages.